Clinical outcomes in rheumatoid arthritis treated with infliximab: Hospital de San José, 2007-2008

Desenlaces clínicos en artritis reumatoidea tratada con infliximab: Hospital de San José, 2007-2008

Objective: to describe the clinical results obtained in patients with rheumatoid arthritis who received infliximab during the period January 2007 to October 2008. Patients and methods: 240 clinical records of RA patients attended during the corresponding period were reviewed, of which 73 they had information available that met the inclusion and exclusion criteria. We analyzed the clinical and sociodemographic characteristics, the behavior of the therapeutic response if there was one and the time of onset, the use of adjuvant drugs and the development of adverse events. Results: 73 patients were described, of which 89.04% were women with an average age of 49.7 years and evolution of RA of 12.0 (± 8.8) years, who received 3 mg / k of infliximab with an average number of doses of 9.1. The therapeutic response was obtained in 52.05% at 24.15 (± 19.5) weeks of treatment. In contrast, the remaining patients who still had no improvement and continued with the treatment, had an average of 26.65 (± 22.5) weeks with the medication. Therapy was suspended in 29 patients: 11 (15.06%) temporarily and 18 (24.65%) permanently. Conclusions: infliximab reduced the inflammatory activity in more than half of the patients of the present study with a low frequency of adverse effects. This response was documented with control in painful and inflamed joints. There was no positive relationship with the inflammatory markers, clarifying the low report of them in the reviewed clinical histories. Abbreviations: AR, rheumatoid arthritis; TNF-a, tumor necrosis factor; CAR, American College of Rheumatology.

1. Ducoulombier V, Solau E, Coquerelle P. Long – term results of Infliximab therapy in rheumatoid arthritis: Experience acquired by the North-Pas-de-Calais hospital network . Joint Bone Spine. 2007 Jan;74(1):56-9

2. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1594-602.

3. Godinho F, Godfrin B. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol. 2004 May-Jun; 22(3):328-30.

4. Williams RO. Pathogenesis and therapy of rheumatoid arthritis. Ernst Schering Found Symp Proc. 2006; 1:107-30.

5. Asociación Colombiana de Reumatología. Grupo de Expertos. Primer consenso colombiano sobre el tratamiento de la artritis reumatoide temprana. Rev. Colomb.Reumatol. 2002 diciembre; 9(4): 323-31.

6. Simon LS. The treatment of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2004 Aug;18(4):507-38

7. Strady C, Brochot P, Ainine K, Jegou J, Remy G, Eschard JP, Jaussaud R. [Tuberculosis during treatment by TNFalpha-inhibitors]. Presse Med. 2006 Nov; 35(11 Pt 2):1765-72.

8. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumour necrosis factor alpha antagonists. Arthritis Rheum. 2007 Apr; 56(4):1125-33.

9. Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol. 2004 May-Jun; 22(3):328-30.

10. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003 Apr;17(2):345-63.

11. Siddiqui MA. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol. 2007 19 (3): 308-13.

12. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis Curr Opin Rheumatol. 2008 Mar; 20(2):138-44.

13. Case JP. Old and New Drugs Used in Rheumatoid Arthritis: A Historical Perspective Part 1: The Older Drugs American Journal of Therapeutics 2001 8, 123–143.

14. John P. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther. 2001 Mar-Apr; 8(2):123-43.

15. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.

16. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford). 2007 Jul; 46(7):1153-6.

17. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006 Sep 15; 43(6):717-22.

18. Maillard H, Ornetti P, Grimault L, Ramon JF, Ducamp SM, Saidani T, Tavernier C, Maillefert JF. Severe pyogenic infections in patients taking infliximab: a regional cohort study. Joint Bone Spine. 2005 Jul; 72(4):330-4.

19. Fuentealba C. ¿Cómo se debe evaluar al paciente con artritis reumatoide en la práctica clínica?. Reumatología. 2003; 19(4):190-93.